Due to recent emergence of resistance to sorafenib (7), second-line therapies targeting other key signaling pathways in HCC, such as the EGFR, WNT, and PI3K-AKT-mTOR pathways [7], are highly desirable. This evidence concerns the gene EGFR and hepatocellular carcinoma.